Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HAIP Chemotherapy After Resection of Colorectal Liver Metastases (Low CRS)
2024-512850-10-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of floxuridine in colorectal cancer (CRC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-512850-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512850-10-00.